Funding profile · Peptide drug discovery

Menten AI

A 2020 seed round of $4M in press reports, $6M in the company’s own account, and no SEC Form D found under any name. Nothing after 2020 is documented.

$4.0MSeed reported by TechCrunch, Jun 30, 2020
$6.0MSeed total in the company’s Jan 2022 release, company-reported
$3.0MThree named checks of $1M each (Khosla, Social Impact Capital, Uncork)
0Form D filings found for Menten AI

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Winter 2020 Y Combinator Not disclosed Y Combinator TechCrunch
Mar 18, 2020 Earlier seed entry Amount not confirmed Not named Tracxn listing
Jun 30, 2020 Seed $4.0M reported Khosla Ventures, Social Impact Capital, Uncork Capital ($1M each); Y Combinator participated TechCrunch
Jan 2022 Seed, as restated USD 6M Uncork Capital, Social Impact Capital, Khosla Ventures, Y Combinator and others Company release
2020 to 2026 Total per data aggregator $4.15M in 2 rounds Y Combinator, Khosla Ventures, Uncork Capital Tracxn
After 2020 Any later round None documented None named Not found

What the filings show

No Form D was found for Menten AI, Inc., for the name Menten Biotechnology Labs, or for any investment vehicle formed to invest in the company. The records file for this profile lists no Form D and no EDGAR mention. A web search of EDGAR filings returned nothing relevant. The money below therefore rests on press reports and company statements, not on filings.

Reading the filings

  1. The announced total and the named checks differ by $1M.TechCrunch reported $4M and said Khosla, Social Impact Capital and Uncork each put in $1M. Three checks of $1M is $3M, so $1M is unattributed. Y Combinator participated, and the rest is not named.
  2. The company later reported a larger seed.A January 2022 release says USD 6 million in seed investment. That is $2M, or 50 percent, above the 2020 report. The gap could reflect later closes or extension money. No source explains it.
  3. Aggregators disagree with both.Tracxn states $4.15M across 2 rounds, close to the press figure and $1.85M below the company’s. Its table lists a Mar 18, 2020 round and a Jun 30, 2020 round with different figures, so its totals cannot be reconciled from the public page.
  4. No filing means no check on investor count.A Form D would show how many investors bought in and how much had been sold. Companies raising under other exemptions, or through convertible notes handled outside Regulation D, file none. The absence does not show that no money moved.
  5. Six years without a documented round.The company has operated through 2026 with a completed Bristol Myers Squibb collaboration on its own account, a 2024 revenue estimate of $2.1M from GetLatka, and about 14 staff in December 2024 by the same source. If those are accurate, the business has been funded by customers, undisclosed capital, or both.

Commercial signals

Signal Detail Source type
Pharma collaboration Completed research collaboration and licensing agreement with Bristol Myers Squibb, announced May 2024. Not confirmed by the partner. Company-stated
Pilots and letters of intent Y Combinator profile: 2 paid pilots with chemical companies and 4 letters of intent, as of the 2020 batch. No later update. Company-stated
Technology partner Xanadu PennyLane partnership, Jan 2022. Company release
Revenue estimate $2.1M for 2024, modeled by GetLatka. Not a filing. Independent estimate
Regulatory and clinical No FDA records or registered trials found. Not found

What to watch

  • A first Form D. It is due within 15 days of the first sale in a Regulation D round.
  • Any statement from Bristol Myers Squibb about the collaboration.
  • A disclosed round that explains the $4M versus $6M difference.
  • Data supporting the MAUD 1.0 performance claims on the company site.

The Menten AI story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Catena Biosciences: Shared investor: Social Impact Capital. A UC Berkeley spinout that uses an engineered tyrosinase to weld two proteins together through their native amino acids, now aimed at antibody drug conjugates carrying
  • Carrot Fertility: Shared investor: Uncork Capital. A benefits platform that sits beside an employer health plan and pays for fertility and family building care
  • MentalHappy: Shared investor: Social Impact Capital. Software for hosting online support groups, sold to individual facilitators and to health organizations
  • Diffuse Bio: Also in Drug Discovery and Delivery. A Y Combinator company founded by one of the researchers who first pointed diffusion models at proteins

Sources

  1. Public recordRecords search for Menten AI: SEC Form D and EDGAR mentions, none foundCompiled Sep 2026
  2. IndependentMenten AI’s combination of buzzword bingo brings AI and quantum computing to drug discoveryTechCrunch · Jun 30, 2020
  3. IndependentMenten AI Announces $4 Million Seed InvestmentInside Quantum Technology · Jun 30, 2020
  4. IndependentMenten AI Raises $4 Million Seed RoundBrownstone Research · Jul 16, 2020
  5. IndependentMenten company profileTracxn
  6. IndependentMenten AI revenue and team estimateGetLatka · 2026
  7. CompanyMenten AI partners with Xanadu, with seed totalPR Newswire · Jan 25, 2022
  8. CompanyCompletion of research collaboration with Bristol Myers SquibbBusiness Wire · May 28, 2024
  9. CompanyMenten AI profileY Combinator

Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Menten AI. This page is not an offer to sell or a recommendation to buy any security.